StudyRareStudyRare
Log in to add personal notes on this page.

A 55-year-old man develops progressive muscle weakness, fasciculations, and atrophy. He has both upper motor neuron signs (spasticity, hyperreflexia) and lower motor neuron signs.

About 10% of people with ALS have an affected relative, and known genes explain at least half of those families; the rest are simplex (one affected person). The best-described mechanisms are a noncoding repeat expansion (C9orf72) and loss of nuclear TDP-43 with cytoplasmic aggregates (TARDBP).

  • AD: C9orf72 (GGGGCC repeat expansion, most common: 39%-45% of familial and 3%-7% of simplex ALS; also causes FTD), SOD1 (15%-20% of familial ALS; AD, or AR for p.Asp90Ala), FUS (~4%-8%), TARDBP (1%-4%)

Genetic ALS reaches motor neuron loss by different routes, and each gene adds its own features:

  • C9orf72: normal 2-24 GGGGCC repeats, 25-60 uncertain, 61 to more than 4,000 pathogenic. The noncoding expansion is thought to act by several hits: expanded RNA traps RNA-binding proteins in nuclear foci; the repeat is translated without a start codon into aggregation-prone dipeptide repeat proteins; and the expanded allele makes less C9orf72 protein (haploinsufficiency). It causes ALS, FTD, or both, with penetrance 50% by age 58 and near 100% by 80. Blood repeat size does not predict onset or severity, and anticipation is unproven.
  • TARDBP: TDP-43 regulates splicing, RNA transport, and local translation from the nucleus. In disease it leaves the nucleus and forms phosphorylated, ubiquitinated aggregates in the cytoplasm, which suggests loss of nuclear function and toxic gain in the cytoplasm together.
  • SOD1: half are symptomatic by age 46. p.Ala4Val, the most common North American variant, may be lower motor neuron predominant and is fatal within 12-18 months of onset.
  • FUS: onset is earlier than with SOD1 or C9orf72, and one third begin with bulbar symptoms.
  • Upper AND lower motor neuron degeneration
  • Progressive weakness, fasciculations, atrophy
  • Bulbar symptoms (dysarthria, dysphagia)
  • Respiratory failure (primary cause of death)
  • C9orf72: GGGGCC hexanucleotide repeat expansion - ALS/FTD spectrum
  • Clinical diagnosis: combined upper and lower motor neuron signs with progression, per El Escorial / Gold Coast criteria
  • EMG/nerve conduction studies confirm lower motor neuron involvement and exclude mimics; neuroimaging excludes structural causes
  • Molecular testing (C9orf72 repeat expansion, then SOD1, TARDBP, FUS) in familial disease or when targeted therapy eligibility matters
  • C9orf72 expansion testing uses repeat-primed PCR; cascade testing offered to at-risk relatives when a familial variant is found
  • Multidisciplinary care (neurology, pulmonology, PT/OT, speech, nutrition) improves survival and quality of life
  • Riluzole and edaravone are approved disease-modifying agents that modestly slow progression
  • SOD1-targeted antisense therapy (tofersen) is indicated for confirmed SOD1-associated ALS
  • Noninvasive ventilation for respiratory failure, PEG for dysphagia/weight loss; advance care planning is central

"A-myo-trophic" = "without muscle nourishment": Motor neurons degenerate, so muscles lose their nerve supply (nourishment) and waste away.

ALS vs Huntington's vs Alzheimer's vs Parkinson's: ALS = motor deficits (fasciculations, weakness). Huntington's = chorea (involuntary movements). Alzheimer's = memory loss. Parkinson's = rigidity and resting tremor.